Overview
Indications
FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
Boxed Warning
FDA Black Box Warning
Warnings and Precautions (5.1) [see]. FINTEPLA can cause valvular heart disease and pulmonary arterial hypertension Dosage and Administration (2.1 2.6 Warnings and Precautions (5.1) [see,) and]. Echocardiogram assessments are required before, during, and after treatment with FINTEPLA. The benefits v
Contraindications
When this intervention should not be used
FINTEPLA is contraindicated in patients with: Description (11) [see] Hypersensitivity to fenfluramine or any of the excipients in FINTEPLA Warnings and Precautions (5.7) [see] Concomitant use, or within 14 days of the administration, of monoamine oxidase inhibitors because of an increased risk of se
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
Clinical Trials
4 trials linked to this intervention
Recent Trials
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age
Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes
Fenfluramine and Cognition
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Specialists
Providers who commonly manage this intervention
Family Medicine — Obesity Medicine
NUCC 207QB0002XInternal Medicine — Obesity Medicine
NUCC 207RB0002XInternal Medicine — Endocrinology, Diabetes & Metabolism
NUCC 207RE0101XHealth Goals
Goals connected through associated conditions
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Fenfluramine (substance)
- SNOMED CT
- 387451002
- UMLS CUI
- C0015827
- RxNorm CUI
- 4328
- Labeler
- UCB, Inc.
Clinical Data
This intervention maps to 11 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.